Researchers found 44 cancer-targeting T cell receptors in routine clinical genomics data from 150,000 tumours. Read how this ...

Novo Nordisk is terminating its cardiometabolic RNA-editing deal with Korro Bio, effective February 2027. Read what it means for Korro's programs and rights.

Anaheim Bio launches with an oversubscribed €40M Series A to advance ANA-1, a CPPD inhibitor, toward the clinic. Learn how ...

Alfasigma's Jyseleca (filgotinib) is now EU-approved for adults with active axial spondyloarthritis. Read what it means for ...

Brii Bio's Phase IIb ENRICH data show BRII-179 priming drove 42% HBsAg loss in hepatitis B. Read the full results and what they mean for a functional cure.

AusperBio reports AHB-137 sustained functional cure in 16 of 17 evaluable NA-treated hepatitis B patients at 12 months off ...

Johnson & Johnson's Rybrevant Faspro earns FDA accelerated approval for recurrent or metastatic HNSCC. Learn who qualifies ...

Roche is using Chai Discovery's AI models across multiple drug discovery programs. Read the full story on this latest 2026 ...

Alamar Biosciences (Nasdaq: ALMR) and Finland-based Nightingale Health have launched UKB-PRISM, a study of 80,000 UK Biobank ...